Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Dec 28, 2022 4:18pm
148 Views
Post# 35194274

RE:RE:RE:RE:RE:RE:What just happened

RE:RE:RE:RE:RE:RE:What just happened
I would like to think you are right with the tax loss selling but do not think so given that in the general sense that the sp was up for the year and also given the 30 day provision that if you sell at a loss you cannot buy back in for 30 days if I remember correctly so those people will not be buying in anytime soon. I think it is just the general malaise in regards to this company as there is no support from management in shares owned or by any institutions in any amount that is meaningful so they will not support the stock. No matter how you look at this,onc is not acting like a company with 2 phase 3 ready indications and 2 fast track designations and with a possible new standard of care for panc. I am not bashing in any sense, just saying that this is not adding up or making any sense in regards to a company with this kind of potential. I wish I had the answeres but do not and neither does anyone on this or any other board. Its all conjecture and wishful thinking and will just have to play out. We can compare all we want with other companies but that will make no difference either. It will all just come down to what someone offers and that will be that. I have been in this stock since 2000 and can't remember the number of years that we were told this will be the year. And don't forget that the mbc supposedly only needed a bio marker as supposedly recommended by the fda and supporting BP that was involved. If this is indeed the case then what is holding them back.
Frustrating for sure to see where we are in the scheme of things and yet the science seems to be more solid than ever for the company so we go on hoping. If something does not happen by Bracelet results or the AGM then something is definitely no right no matter how one looks at it and then there can be no more excuses. Looking forward to an interesting next 6 months or hopefully less and please a buyout so we do not have to deal with any of the bs anymore.
<< Previous
Bullboard Posts
Next >>